Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 15

1.

Estradiol and mTORC2 cooperate to enhance prostaglandin biosynthesis and tumorigenesis in TSC2-deficient LAM cells.

Li C, Lee PS, Sun Y, Gu X, Zhang E, Guo Y, Wu CL, Auricchio N, Priolo C, Li J, Csibi A, Parkhitko A, Morrison T, Planaguma A, Kazani S, Israel E, Xu KF, Henske EP, Blenis J, Levy BD, Kwiatkowski D, Yu JJ.

J Exp Med. 2014 Jan 13;211(1):15-28. doi: 10.1084/jem.20131080. Epub 2014 Jan 6.

PMID:
24395886
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

eIF3f: a central regulator of the antagonism atrophy/hypertrophy in skeletal muscle.

Sanchez AM, Csibi A, Raibon A, Docquier A, Lagirand-Cantaloube J, Leibovitch MP, Leibovitch SA, Bernardi H.

Int J Biochem Cell Biol. 2013 Oct;45(10):2158-62. doi: 10.1016/j.biocel.2013.06.001. Epub 2013 Jun 13. Review.

PMID:
23769948
[PubMed - indexed for MEDLINE]
3.

Metformin decreases glucose oxidation and increases the dependency of prostate cancer cells on reductive glutamine metabolism.

Fendt SM, Bell EL, Keibler MA, Davidson SM, Wirth GJ, Fiske B, Mayers JR, Schwab M, Bellinger G, Csibi A, Patnaik A, Blouin MJ, Cantley LC, Guarente L, Blenis J, Pollak MN, Olumi AF, Vander Heiden MG, Stephanopoulos G.

Cancer Res. 2013 Jul 15;73(14):4429-38. doi: 10.1158/0008-5472.CAN-13-0080. Epub 2013 May 17.

PMID:
23687346
[PubMed - indexed for MEDLINE]
Free PMC Article
4.

The mTORC1 pathway stimulates glutamine metabolism and cell proliferation by repressing SIRT4.

Csibi A, Fendt SM, Li C, Poulogiannis G, Choo AY, Chapski DJ, Jeong SM, Dempsey JM, Parkhitko A, Morrison T, Henske EP, Haigis MC, Cantley LC, Stephanopoulos G, Yu J, Blenis J.

Cell. 2013 May 9;153(4):840-54. doi: 10.1016/j.cell.2013.04.023.

PMID:
23663782
[PubMed - indexed for MEDLINE]
Free PMC Article
5.

SIRT4 has tumor-suppressive activity and regulates the cellular metabolic response to DNA damage by inhibiting mitochondrial glutamine metabolism.

Jeong SM, Xiao C, Finley LW, Lahusen T, Souza AL, Pierce K, Li YH, Wang X, Laurent G, German NJ, Xu X, Li C, Wang RH, Lee J, Csibi A, Cerione R, Blenis J, Clish CB, Kimmelman A, Deng CX, Haigis MC.

Cancer Cell. 2013 Apr 15;23(4):450-63. doi: 10.1016/j.ccr.2013.02.024. Epub 2013 Apr 4.

PMID:
23562301
[PubMed - indexed for MEDLINE]
Free PMC Article
6.

Hippo-YAP and mTOR pathways collaborate to regulate organ size.

Csibi A, Blenis J.

Nat Cell Biol. 2012 Dec;14(12):1244-5. doi: 10.1038/ncb2634.

PMID:
23196842
[PubMed - indexed for MEDLINE]
7.

The role of AMP-activated protein kinase in the coordination of skeletal muscle turnover and energy homeostasis.

Sanchez AM, Candau RB, Csibi A, Pagano AF, Raibon A, Bernardi H.

Am J Physiol Cell Physiol. 2012 Sep 1;303(5):C475-85. doi: 10.1152/ajpcell.00125.2012. Epub 2012 Jun 13. Review.

PMID:
22700795
[PubMed - indexed for MEDLINE]
Free Article
8.

Appetite for destruction: the inhibition of glycolysis as a therapy for tuberous sclerosis complex-related tumors.

Csibi A, Blenis J.

BMC Biol. 2011 Oct 21;9:69. doi: 10.1186/1741-7007-9-69. Review.

PMID:
22018140
[PubMed - indexed for MEDLINE]
Free PMC Article
9.

AMPK promotes skeletal muscle autophagy through activation of forkhead FoxO3a and interaction with Ulk1.

Sanchez AM, Csibi A, Raibon A, Cornille K, Gay S, Bernardi H, Candau R.

J Cell Biochem. 2012 Feb;113(2):695-710. doi: 10.1002/jcb.23399.

PMID:
22006269
[PubMed - indexed for MEDLINE]
10.

Angiotensin II inhibits insulin-stimulated GLUT4 translocation and Akt activation through tyrosine nitration-dependent mechanisms.

Csibi A, Communi D, Müller N, Bottari SP.

PLoS One. 2010 Apr 7;5(4):e10070. doi: 10.1371/journal.pone.0010070.

PMID:
20383279
[PubMed - indexed for MEDLINE]
Free PMC Article
11.

The translation regulatory subunit eIF3f controls the kinase-dependent mTOR signaling required for muscle differentiation and hypertrophy in mouse.

Csibi A, Cornille K, Leibovitch MP, Poupon A, Tintignac LA, Sanchez AM, Leibovitch SA.

PLoS One. 2010 Feb 1;5(2):e8994. doi: 10.1371/journal.pone.0008994.

PMID:
20126553
[PubMed - indexed for MEDLINE]
Free PMC Article
12.

Inhibition of atrogin-1/MAFbx mediated MyoD proteolysis prevents skeletal muscle atrophy in vivo.

Lagirand-Cantaloube J, Cornille K, Csibi A, Batonnet-Pichon S, Leibovitch MP, Leibovitch SA.

PLoS One. 2009;4(3):e4973. doi: 10.1371/journal.pone.0004973. Epub 2009 Mar 25.

PMID:
19319192
[PubMed - indexed for MEDLINE]
Free PMC Article
13.

MAFbx/Atrogin-1 controls the activity of the initiation factor eIF3-f in skeletal muscle atrophy by targeting multiple C-terminal lysines.

Csibi A, Leibovitch MP, Cornille K, Tintignac LA, Leibovitch SA.

J Biol Chem. 2009 Feb 13;284(7):4413-21. doi: 10.1074/jbc.M807641200. Epub 2008 Dec 10.

PMID:
19073596
[PubMed - indexed for MEDLINE]
Free Article
14.

eIF3-f function in skeletal muscles: to stand at the crossroads of atrophy and hypertrophy.

Csibi A, Tintignac LA, Leibovitch MP, Leibovitch SA.

Cell Cycle. 2008 Jun 15;7(12):1698-701. Epub 2008 Jun 11.

PMID:
18583931
[PubMed - indexed for MEDLINE]
Free Article
15.

The initiation factor eIF3-f is a major target for atrogin1/MAFbx function in skeletal muscle atrophy.

Lagirand-Cantaloube J, Offner N, Csibi A, Leibovitch MP, Batonnet-Pichon S, Tintignac LA, Segura CT, Leibovitch SA.

EMBO J. 2008 Apr 23;27(8):1266-76. doi: 10.1038/emboj.2008.52. Epub 2008 Mar 20.

PMID:
18354498
[PubMed - indexed for MEDLINE]
Free PMC Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk